Project Grant R41EY034424
Award Date
9/30/22
Completion Date
9/29/23
Dollars Obligated
$480K
Federal Agency
National Eye Institute
Federal Grant Program
93.867
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92093, USA
Similar Awards
This National Eye Institute (NEI) Project Grant award (CFDA 93.867 - Vision Research) for $715,098 aims to enhance glaucoma risk prediction through advanced genomics and machine learning techniques. The key products and services to be delivered under this 5-year project include: Improving polygenic risk score (PRS) performance for glaucoma by leveraging enhanced electronic health record (EHR) data phenotyping using natural language processing (NLP) on over 68,000 patient records across two...
The National Eye Institute (NEI) awarded a $654,455 Project Grant under the Vision Research federal grant program (CFDA 93.867) to The Leland Stanford Junior University. The grant will fund a project titled "Improving Fairness and Reducing Bias in Artificial Intelligence Algorithms for Glaucoma" over a period of 5 years from January 1, 2025 to December 31, 2029. The project aims to develop fair and generalizable prediction algorithms for glaucoma progression using electronic health...
This Project Grant award from the National Eye Institute (CFDA 93.867 Vision Research) provides $628,531 to the University of Miami to validate and implement an artificial intelligence (AI) machine-to-machine (M2M) model for equitable glaucoma screening in underserved populations. The key objectives are to: 1) refine the M2M model using large clinic and population-based datasets to ensure effective and equitable glaucoma screening across diverse groups; 2) implement the M2M model for...
The National Eye Institute (NEI), through its Vision Research program (CFDA 93.867), awarded a $881,796 Project Grant to Siloam Vision, Inc. to develop two advanced, laser-based, artificial intelligence (AI)-enabled retinal imaging systems. The primary goal is to address the unmet need for cost-effective and less stressful methods to diagnose and monitor retinopathy of prematurity (ROP), a leading cause of childhood blindness. The key innovations include: 1) A wider field-of-view camera design...
This federal Project Grant award from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) provides $754,779 to develop equitable deep learning models for automated glaucoma screening. The project aims to assess the performance equity of existing deep learning models for glaucoma detection and develop novel equity-aware techniques, including fair identity scaling, identity-conditioned generative models, and fair identity normalization. These approaches aim to...
This $306,462 Project Grant awarded by the National Eye Institute (NEI) under the Vision Research federal grant program (CFDA 93.867) will fund the development of a software platform called OCT-ART-DR. The platform will automate the diagnosis and staging of diabetic retinopathy (DR), a leading cause of blindness, using optical coherence tomography angiography (OCTA) imaging and artificial intelligence (AI). The key products to be delivered include: 1) Improved AI-based segmentation of OCTA image...
The National Eye Institute (NEI) has awarded a $466,125 Federal Project Grant (CFDA 93.867 - Vision Research) to Weill Medical College of Cornell University to develop and validate a new artificial intelligence approach to improve the fairness of predictive models for primary open-angle glaucoma (POAG) risk estimation. The project aims to study algorithmic bias in POAG risk prediction and examine the impact of transferring bias from a biased model to a demographically balanced dataset. The...
The National Eye Institute (NEI) awarded a $1,757,548 Project Grant (CFDA 93.867 Vision Research) to the University of Wisconsin-Madison to investigate an AI-based system that allows primary care providers to identify and address diabetic eye disease without the need for oversight by an eye care provider. The project, known as AI-Bridge, aims to improve eye screening and follow-up care rates, particularly among racial/ethnic minorities and socioeconomically disadvantaged communities. Key...
The National Eye Institute (NEI) awarded a $1,066,178 Project Grant under the 93.867 Vision Research program to Tavo Biotherapeutics, Inc. (operating as Oculo Therapy LLC), a woman-owned small business. The funding supports late-stage preclinical development and GMP production of a novel, extended-release intraocular pressure (IOP)-lowering topical formulation using the FDA-approved drug pregabalin to address significant unmet needs in glaucoma treatment. The key aims are to develop a...
The National Eye Institute (NEI) awarded a $360,897 Project Grant (CFDA 93.867 - Vision Research) to Human Cell Co, a for-profit biotechnology research and development company located in Naperville, Illinois. The grant funding will support a Phase 1 study to determine whether combining topical administration of a novel nerve growth factor (NGF) mutein, HC201, with oral nicotinamide (NAM) supplementation can more effectively improve retinal ganglion cell (RGC) function compared to either...